A newer class of bone-building medication, most notably romosozumab (sold under the brand name Evenity), has shown remarkable results in clinical trials, outperforming older osteoporosis treatments at actually rebuilding bone rather than simply slowing its breakdown. For people with dementia or cognitive decline who are already at elevated fall risk, this kind of drug could be a genuine game-changer — fractures in this population are not just painful but often catastrophic, accelerating decline and sometimes proving fatal.
The problem is that romosozumab carries a price tag that has historically run into the tens of thousands of dollars per year, and many insurance plans, including some Medicare Part D formularies, have either refused to cover it or buried it behind so many prior authorization hoops that patients and caregivers give up before they ever fill the prescription. This article breaks down what romosozumab actually does differently from older osteoporosis drugs, why insurance coverage remains so inconsistent, and what the real-world implications are for dementia caregivers trying to protect a loved one from a hip fracture that could end their independence permanently. We will also look at the appeal and prior authorization process, alternative bone-building options, and the particular challenges facing people with cognitive impairment who cannot always advocate for themselves in a fragmented healthcare system.
Table of Contents
- Why Does This New Bone-Building Drug Outperform Older Osteoporosis Treatments?
- What Makes Insurance Coverage for Romosozumab So Difficult to Obtain?
- The Fracture Crisis in Dementia Care
- Navigating Prior Authorization and Appeals for Bone-Building Drugs
- Cardiovascular Warnings and Who Should Not Take Romosozumab
- Manufacturer Assistance Programs and Alternative Coverage Pathways
- Where Bone Health Treatment in Dementia Is Headed
- Conclusion
- Frequently Asked Questions
Why Does This New Bone-Building Drug Outperform Older Osteoporosis Treatments?
Most osteoporosis drugs prescribed over the past two decades — bisphosphonates like alendronate (Fosamax) and risedronate (Actonel), along with the injectable denosumab (Prolia) — work by slowing down the cells that break bone apart. They are anti-resorptive drugs, meaning they pump the brakes on bone loss but do relatively little to build new bone tissue. Romosozumab works through a fundamentally different mechanism. It inhibits a protein called sclerostin, which normally acts as a brake on bone formation. By blocking that brake, romosozumab essentially tells the body to ramp up new bone production while simultaneously reducing bone breakdown. The result, demonstrated in the landmark ARCH and FRAME clinical trials, was a significant reduction in vertebral and clinical fractures compared to both placebo and alendronate over a 12-month treatment period. The clinical difference is not subtle.
In the ARCH trial, patients who received romosozumab for 12 months followed by alendronate had notably fewer new vertebral fractures and hip fractures compared to those who received alendronate alone for the entire period. For a person with moderate dementia who takes a fall in the bathroom — something that happens with alarming regularity — the difference between a bone that can absorb some impact and one that shatters on contact is the difference between a bruise and a surgery that may never fully heal. Teriparatide (Forteo), an older bone-building drug, also stimulates new bone formation, but romosozumab appears to produce faster gains in bone mineral density over its 12-month treatment course, and it is administered as a monthly injection rather than a daily one, which matters enormously when the patient cannot remember to self-inject. However, romosozumab is not without risk. The FDA required a boxed warning about potential cardiovascular events, including heart attack and stroke, after the ARCH trial showed a numerical imbalance in these events compared to alendronate. For patients who already have cardiovascular risk factors — and many older adults with dementia do — this is not a trivial concern. Physicians have to weigh the fracture reduction against the cardiovascular signal, and for some patients, the drug simply is not appropriate.
What Makes Insurance Coverage for Romosozumab So Difficult to Obtain?
The core issue is cost. Romosozumab has historically been priced at a level that makes insurance companies hesitant to approve it without substantial documentation that cheaper alternatives have already been tried and failed. This typically means a patient must demonstrate that they have used and either not tolerated or not responded to bisphosphonates, and sometimes denosumab or teriparatide as well, before the insurer will even consider covering romosozumab. The prior authorization process can involve submitting bone density scan results, fracture history, documentation of failed therapies, and sometimes a peer-to-peer review between the prescribing physician and an insurance company medical director. For dementia caregivers, this bureaucratic gauntlet is particularly punishing. The person who needs the drug may not be able to articulate their symptoms, remember their medication history, or participate in medical decision-making at all. The caregiver — often a spouse or adult child already stretched beyond capacity — is left to coordinate between an endocrinologist or rheumatologist, a primary care physician, a pharmacy, and an insurance company’s utilization management department.
If the prior authorization is denied, the appeal process requires even more paperwork and follow-up, and many families simply do not have the bandwidth to pursue it. Medicare coverage adds another layer of complexity. Because romosozumab is administered as a subcutaneous injection in a medical office, it may fall under Medicare Part B rather than Part D, depending on how it is billed. Part B generally covers drugs administered by a healthcare provider, while Part D covers self-administered medications. The distinction matters because coverage rules, copay structures, and appeal processes differ between the two parts. Some patients have reported being bounced between Part B and Part D with neither side willing to pick up the cost. If your loved one has a Medicare Advantage plan, the rules may differ yet again, and the network restrictions can limit which specialists are available to prescribe and administer the drug in the first place.
The Fracture Crisis in Dementia Care
Hip fractures in people with dementia are not just orthopedic events — they are frequently the beginning of a rapid and irreversible decline. Research has consistently shown that people with dementia who sustain a hip fracture have significantly higher mortality rates in the year following the fracture compared to cognitively intact individuals with the same injury. They are less able to participate in rehabilitation, more likely to develop delirium in the hospital, and more likely to be discharged to a long-term care facility rather than returning home. A study published in the Journal of the American Geriatrics Society found that dementia patients with hip fractures had roughly double the one-year mortality rate of hip fracture patients without dementia. The tragedy is compounded by the fact that many of these fractures are preventable, or at least their severity can be reduced, with appropriate osteoporosis treatment. Yet people with dementia are systematically undertreated for osteoporosis.
Physicians may be reluctant to prescribe medications to patients who cannot consent to treatment or who have a limited life expectancy. Caregivers may not think to ask about bone health when they are consumed with managing behavioral symptoms, wandering, or incontinence. The result is a population that is simultaneously at the highest risk for fractures and the least likely to receive the drugs that could prevent them. Consider a scenario that plays out in memory care facilities across the country every week: a resident with moderate Alzheimer’s disease gets up at night, disoriented, catches a foot on the bed frame, and falls. If that person has been on a bone-building regimen, the femur may hold. If not, the ambulance comes, the surgery follows, and the confusion and pain of recovery in an unfamiliar hospital environment often accelerates cognitive decline in ways that never fully reverse.
Navigating Prior Authorization and Appeals for Bone-Building Drugs
If your loved one’s physician recommends romosozumab and the insurer denies coverage, the first step is to request a formal written denial with the specific reason stated. Insurance companies are required to provide this, and the denial letter is the roadmap for your appeal. Common denial reasons include failure to try cheaper alternatives first, insufficient documentation of fracture risk, or a determination that the drug is not medically necessary for the patient’s specific situation. The appeal process typically involves the prescribing physician writing a letter of medical necessity that addresses the insurer’s specific objections. This letter should include bone density scores (T-scores from a DEXA scan), a history of prior fractures, documentation of failed or contraindicated prior therapies, and an explanation of why the patient’s particular circumstances — including their dementia diagnosis and elevated fall risk — make romosozumab the appropriate choice.
Some insurers will accept a peer-to-peer conversation between the prescribing doctor and the insurer’s medical reviewer, which can sometimes resolve the issue faster than a written appeal. If the first-level appeal fails, most plans offer a second-level or external appeal, and in the case of Medicare, there is a structured multi-level appeal process that can eventually reach an administrative law judge. The tradeoff is time versus outcome. Pursuing an appeal can take weeks to months, and during that period, the patient’s bones continue to thin and their fracture risk remains elevated. Some physicians will start a patient on a bisphosphonate or denosumab as a bridge therapy while the appeal is pending, which is a reasonable compromise but not equivalent to the bone-building effect of romosozumab. Patient advocacy organizations, including some osteoporosis foundations, may offer assistance navigating the appeals process, and the drug’s manufacturer has historically maintained a patient assistance program for those who qualify based on income, though eligibility criteria and availability can change.
Cardiovascular Warnings and Who Should Not Take Romosozumab
The boxed warning on romosozumab regarding cardiovascular risk is not something to dismiss or minimize. The ARCH trial data showed a higher rate of serious cardiovascular events — including myocardial infarction, stroke, and cardiovascular death — in the romosozumab group compared to the alendronate group during the first 12 months of treatment. The FDA’s labeling explicitly states that romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year, and it advises physicians to consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. For the dementia population, this warning creates a genuine clinical dilemma. Many people with Alzheimer’s disease and other dementias also have cardiovascular disease, hypertension, diabetes, or a history of stroke. Vascular dementia, by definition, involves cerebrovascular damage.
A physician evaluating whether to prescribe romosozumab to a patient with mixed dementia — some Alzheimer’s pathology, some vascular pathology — has to weigh the real and demonstrated benefit of fracture prevention against a cardiovascular risk signal that, while not conclusively causal, cannot be ignored. There is no clean answer here, and families should expect a frank conversation about tradeoffs rather than a simple yes or no. It is also worth noting that romosozumab is approved for only 12 monthly doses. It is not a lifelong therapy. After the 12-month course, patients are typically transitioned to an anti-resorptive drug like denosumab or a bisphosphonate to maintain the bone density gains. If that transition does not happen — if, for example, a caregiver loses track of the medication schedule or a physician does not follow up — the bone density gains can be lost relatively quickly. This is a particular risk for dementia patients whose care may be fragmented across multiple providers.
Manufacturer Assistance Programs and Alternative Coverage Pathways
The manufacturer of romosozumab, Amgen, has historically offered patient support programs that can help reduce out-of-pocket costs for eligible patients. These programs have typically included copay assistance for commercially insured patients and, in some cases, free drug programs for uninsured or underinsured individuals who meet income thresholds. Eligibility and program details change over time, so caregivers should contact the manufacturer directly or ask the prescribing physician’s office to connect them with a patient access specialist.
Some specialty pharmacies also have staff dedicated to navigating coverage and financial assistance for high-cost biologics. State pharmaceutical assistance programs (SPAPs) may offer additional help in some jurisdictions, and certain nonprofit organizations provide grants to help cover medication costs for older adults. The key is persistence — the landscape of patient assistance is fragmented, and no single source will hand you a comprehensive list of every program your loved one might qualify for.
Where Bone Health Treatment in Dementia Is Headed
There is growing recognition in geriatric medicine that fracture prevention needs to be treated as a core component of dementia care, not an afterthought. Some memory care programs and geriatric practices are beginning to incorporate routine bone density screening and fall risk assessment into their standard evaluations for new dementia patients, rather than waiting for a fracture to occur before addressing bone health.
As the evidence base around romosozumab matures and potential biosimilar competitors enter the pipeline, there is cautious hope that costs may come down and coverage may become less restrictive. The broader question is whether the healthcare system will adapt to the reality that people with dementia cannot navigate prior authorization processes, cannot self-advocate with insurance companies, and cannot manage complex medication transitions on their own. Until the system makes it easier for caregivers to access effective treatments without months of bureaucratic wrangling, the most vulnerable patients will continue to be undertreated — and the fractures will keep coming.
Conclusion
Romosozumab represents a genuine advance in osteoporosis treatment, offering bone-building capabilities that older drug classes simply cannot match. For people with dementia, who face an outsized fracture risk and devastating consequences when fractures occur, access to this drug could meaningfully change outcomes. But the gap between what the science shows and what insurance will cover remains wide, and the burden of closing that gap falls almost entirely on caregivers who are already overwhelmed.
If you are caring for someone with dementia and osteoporosis, start the conversation about bone health with their physician now, before a fracture forces the issue. Ask about bone density screening, review their fall risk, and if romosozumab is recommended, be prepared to engage with the prior authorization and appeal process. Document everything, ask the prescribing physician’s office for help with paperwork, and explore manufacturer assistance programs. The system will not make this easy, but the stakes — your loved one’s mobility, independence, and life — are too high to leave bone health unaddressed.
Frequently Asked Questions
Is romosozumab safe for someone with Alzheimer’s disease?
There is no specific contraindication for Alzheimer’s disease itself. The primary safety concern is cardiovascular risk. If the patient has a history of heart attack, stroke, or significant cardiovascular disease, the drug may not be appropriate. A physician should evaluate the individual’s full medical history before prescribing.
How is romosozumab administered, and can a caregiver give the injection?
Romosozumab is given as two subcutaneous injections once a month, typically in a healthcare provider’s office. It is not generally self-administered at home, which means the patient or caregiver needs to arrange monthly office visits for 12 months.
What happens after the 12-month course of romosozumab ends?
Patients are usually transitioned to an anti-resorptive medication such as denosumab or a bisphosphonate to maintain bone density gains. Without follow-up therapy, the improvements in bone density can diminish over time.
Does Medicare cover romosozumab?
Coverage varies. Because it is administered in a medical office, it may fall under Medicare Part B. However, coverage often requires prior authorization, and some Medicare Advantage plans have additional restrictions. Denials can be appealed through Medicare’s structured appeal process.
Are there alternatives to romosozumab for building bone?
Teriparatide (Forteo) and abaloparatide (Tymlos) are also anabolic bone-building drugs, though they work through a different mechanism and are typically administered as daily self-injections. They may be covered more readily by some insurance plans and can be reasonable alternatives, though the daily injection requirement is a significant barrier for dementia patients.
